(Q51386964)

English

Biorelevant in vitro dissolution testing of products containing micronized or nanosized fenofibrate with a view to predicting plasma profiles

scientific article published on November 11, 2010

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21074611

Biorelevant in vitro dissolution testing of products containing micronized or nanosized fenofibrate with a view to predicting plasma profiles (English)

1 reference

10.1016/J.EJPB.2010.10.012

https://api.crossref.org/works/10.1016/J.EJPB.2010.10.012

26 August 2024

Christos Reppas

4

object named as

Christos Reppas

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21074611

26 August 2024

author name string

Daniel Juenemann

1

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21074611

Ekarat Jantratid

2

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21074611

Christian Wagner

3

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21074611

Maria Vertzoni

5

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21074611

Jennifer B. Dressman

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21074611

26 August 2024

language of work or name

0 references

publication date

11 November 2010

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21074611

full work available at URL

https://api.elsevier.com/content/article/PII:S0939641110002869?httpAccept=text/xml

1 reference

10.1016/J.EJPB.2010.10.012

https://api.crossref.org/works/10.1016/J.EJPB.2010.10.012

26 August 2024

https://api.elsevier.com/content/article/PII:S0939641110002869?httpAccept=text/plain

1 reference

10.1016/J.EJPB.2010.10.012

https://api.crossref.org/works/10.1016/J.EJPB.2010.10.012

26 August 2024

European Journal of Pharmaceutics and Biopharmaceutics

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21074611

77

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21074611

2

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21074611

257-264

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21074611

Effect of particle size on the bioavailability of digoxin

1

1 reference

10.1016/J.EJPB.2010.10.012

https://api.crossref.org/works/10.1016/J.EJPB.2010.10.012

26 August 2024

Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs

2

1 reference

10.1016/J.EJPB.2010.10.012

https://api.crossref.org/works/10.1016/J.EJPB.2010.10.012

26 August 2024

Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs

3

1 reference

10.1016/J.EJPB.2010.10.012

https://api.crossref.org/works/10.1016/J.EJPB.2010.10.012

26 August 2024

Mixing-tank model for predicting dissolution rate control or oral absorption

4

1 reference

10.1016/J.EJPB.2010.10.012

https://api.crossref.org/works/10.1016/J.EJPB.2010.10.012

26 August 2024

Nanosizing--oral formulation development and biopharmaceutical evaluation

5

1 reference

10.1016/J.EJPB.2010.10.012

https://api.crossref.org/works/10.1016/J.EJPB.2010.10.012

26 August 2024

Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future.

6

1 reference

10.1016/J.EJPB.2010.10.012

https://api.crossref.org/works/10.1016/J.EJPB.2010.10.012

26 August 2024

Nanosuspensions in drug delivery

7

1 reference

10.1016/J.EJPB.2010.10.012

https://api.crossref.org/works/10.1016/J.EJPB.2010.10.012

26 August 2024

Particle uptake and translocation across epithelial membranes

9

1 reference

10.1016/J.EJPB.2010.10.012

https://api.crossref.org/works/10.1016/J.EJPB.2010.10.012

26 August 2024

The oral absorption of micro- and nanoparticulates: neither exceptional nor unusual

10

1 reference

10.1016/J.EJPB.2010.10.012

https://api.crossref.org/works/10.1016/J.EJPB.2010.10.012

26 August 2024

Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications

11

1 reference

10.1016/J.EJPB.2010.10.012

https://api.crossref.org/works/10.1016/J.EJPB.2010.10.012

26 August 2024

A physicochemical basis for the effect of food on the absolute oral bioavailability of halofantrine

12

1 reference

10.1016/J.EJPB.2010.10.012

https://api.crossref.org/works/10.1016/J.EJPB.2010.10.012

26 August 2024

Absence of a food effect with a 145 mg nanoparticle fenofibrate tablet formulation.

14

1 reference

10.1016/J.EJPB.2010.10.012

https://api.crossref.org/works/10.1016/J.EJPB.2010.10.012

26 August 2024

IVIVC in oral absorption for fenofibrate immediate release tablets using a dissolution/permeation system

16

1 reference

10.1016/J.EJPB.2010.10.012

https://api.crossref.org/works/10.1016/J.EJPB.2010.10.012

26 August 2024

Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update

17

1 reference

10.1016/J.EJPB.2010.10.012

https://api.crossref.org/works/10.1016/J.EJPB.2010.10.012

26 August 2024

Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms

18

1 reference

10.1016/J.EJPB.2010.10.012

https://api.crossref.org/works/10.1016/J.EJPB.2010.10.012

26 August 2024

Simulation of fasting gastric conditions and its importance for the in vivo dissolution of lipophilic compounds

19

1 reference

10.1016/J.EJPB.2010.10.012

https://api.crossref.org/works/10.1016/J.EJPB.2010.10.012

26 August 2024

Forecasting the in vivo performance of four low solubility drugs from their in vitro dissolution data

20

1 reference

10.1016/J.EJPB.2010.10.012

https://api.crossref.org/works/10.1016/J.EJPB.2010.10.012

26 August 2024

Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs

21

1 reference

10.1016/J.EJPB.2010.10.012

https://api.crossref.org/works/10.1016/J.EJPB.2010.10.012

26 August 2024

Application of biorelevant dissolution tests to the prediction of in vivo performance of diclofenac sodium from an oral modified-release pellet dosage form

22

1 reference

10.1016/J.EJPB.2010.10.012

https://api.crossref.org/works/10.1016/J.EJPB.2010.10.012

26 August 2024

Designing biorelevant dissolution tests for lipid formulations: case example--lipid suspension of RZ-50.

23

1 reference

10.1016/J.EJPB.2010.10.012

https://api.crossref.org/works/10.1016/J.EJPB.2010.10.012

26 August 2024

Dissolution enhancement of fenofibrate by micronization, cogrinding and spray-drying: comparison with commercial preparations

24

1 reference

10.1016/J.EJPB.2010.10.012

https://api.crossref.org/works/10.1016/J.EJPB.2010.10.012

26 August 2024

Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling

25

1 reference

10.1016/J.EJPB.2010.10.012

https://api.crossref.org/works/10.1016/J.EJPB.2010.10.012

26 August 2024

Biorelevant dissolution testing to predict the plasma profile of lipophilic drugs after oral administration

28

1 reference

10.1016/J.EJPB.2010.10.012

https://api.crossref.org/works/10.1016/J.EJPB.2010.10.012

26 August 2024

Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug

29

1 reference

10.1016/J.EJPB.2010.10.012

https://api.crossref.org/works/10.1016/J.EJPB.2010.10.012

26 August 2024

The basics and underlying mechanisms of mucoadhesion

32

1 reference

10.1016/J.EJPB.2010.10.012

https://api.crossref.org/works/10.1016/J.EJPB.2010.10.012

26 August 2024

Evaluation of nano- and microparticle uptake by the gastrointestinal tract

33

1 reference

10.1016/J.EJPB.2010.10.012

https://api.crossref.org/works/10.1016/J.EJPB.2010.10.012

26 August 2024

Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans

34

1 reference

10.1016/J.EJPB.2010.10.012

https://api.crossref.org/works/10.1016/J.EJPB.2010.10.012

26 August 2024

Bioavailability and bioequivalence: focus on physiological factors and variability.

35

1 reference

10.1016/J.EJPB.2010.10.012

https://api.crossref.org/works/10.1016/J.EJPB.2010.10.012

26 August 2024

Effects of protein on glycemic and incretin responses and gastric emptying after oral glucose in healthy subjects

36

1 reference

10.1016/J.EJPB.2010.10.012

https://api.crossref.org/works/10.1016/J.EJPB.2010.10.012

26 August 2024

Identifiers

10.1016/J.EJPB.2010.10.012

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21074611

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21074611

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51386964&oldid=2236255226"